R. Rea

发表

The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.

F. Amenta, E. Traini, G. Ricci, 2017, Journal of Alzheimer's disease : JAD.

Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review

F. Amenta, A. Fasanaro, R. Rea, 2012, Journal of experimental pharmacology.

Cognitive Assessment of Patients With Alzheimer's Disease by Telemedicine: Pilot Study

F. Amenta, E. Traini, G. Ricci, 2018, JMIR mental health.

The ASCOMALVA trial: Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: Interim results

F. Amenta, E. Traini, A. Carotenuto, 2012, Journal of the Neurological Sciences.

Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.

F. Amenta, E. Traini, A. Carotenuto, 2015, Journal of Alzheimer's disease : JAD.

Late and early onset dementia: What is the role of vascular factors? A retrospective study

F. Amenta, E. Traini, A. Carotenuto, 2012, Journal of the Neurological Sciences.

Apathy in Alzheimer's Disease: Any Effective Treatment?

F. Amenta, E. Traini, A. Carotenuto, 2014, TheScientificWorldJournal.

Efficacy and impact on cognitive functions and quality of life of perampanel as first add-on therapy in patients with epilepsy: A retrospective study

E. Traini, R. Rea, M. Pezzella, 2019, Epilepsy & Behavior.

The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.

F. Amenta, E. Traini, A. Carotenuto, 2014, Journal of Alzheimer's disease : JAD.